Top

Osteoporosis International

Published in:

01-03-2015 | Original Article

Local renin-angiotensin system is associated with bone mineral density of glucocorticoid-induced osteoporosis patients

Authors: B. Shuai, Y. P. Yang, L. Shen, R. Zhu, X. J. Xu, C. Ma, L. Lv, J. Zhao, J. H. Rong

Published in: Osteoporosis International | Issue 3/2015

Abstract

Summary

The local renin-angiotensin system (RAS) is closely related to bone metabolism. However, it is unknown whether the local RAS is related to bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIOP). Here, we revealed that the two main characteristics of GIOP might inhibit bone formation and enhance bone resorption.

Introduction

The aim of this study is to assess the expression of the main RAS components in the trabecular bone of lumbar vertebrae in GIOP and analyze the relationship between the major RAS components and BMD.

Methods

We collected 96 inpatient cases of lumbar disc herniation from patients who underwent dual-energy X-ray absorptiometry examinations followed by surgical treatment in our hospital. Patients were divided into the GIOP group (n = 48) and control group (n = 48). The circulating and local expression levels of the main RAS components were examined. The correlation between the main RAS components and BMD was then analyzed.

Results

The mRNA expression of local bone angiotensin type 1 and 2 receptors (AT1R and AT2R, respectively) and RANKL was higher in the GIOP group compared with the control group (p < 0.001), but there was no difference in the circulating protein levels between groups (p > 0.05). Multiple logistic regression analysis revealed that AT1R and AT2R expression and the RANKL/OPG ratio in local bone were negatively associated with BMD (p < 0.001, odds ratio (OR) 1.236, 95 % confidence interval (CI) 1.207–1.333; p < 0.001, OR 1.971, 95 % CI 1.809–2.233; and p < 0.001, OR 1.676, 95 % CI 1.546–1.845, respectively).

Conclusion

This study provides evidence that the role of local RAS is related to BMD in GIOP patients, and suggests that local RAS might influence RANKL/OPG signaling to modulate bone metabolism.

van Staa TP, Geusens P, Pols HA, de Laet C, Leufkens HG, Cooper C (2005) A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM 98:191–198CrossRefPubMed

van Staa TP (2006) The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79:129–137CrossRefPubMed

Rizzoli R, Adachi JD, Cooper C, Dere W, Devogelaer JP, Diez-Perez A, Kanis JA, Laslop A, Mitlak B, Papapoulos S, Ralston S, Reiter S, Werhya G, Reginster JY (2012) Management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 91:225–243CrossRefPubMed

Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE; Joint IOF-ECTS GIO Guidelines Working Group (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276CrossRef

Hagiwara H, Hiruma Y, Inoue A, Yamaguchi A, Hirose S (1998) Deceleration by angiotensin II of the differentiation and bone formation of rat calvarial osteoblastic cells. J Endocrinol 156:543–550CrossRefPubMed

Hatton R, Stimpel M, Chambers TJ (1997) Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J Endocrinol 152:5–10CrossRefPubMed

Liu YY, Yao WM, Wu T, Xu BL, Chen F, Cui L (2011) Captopril improves osteopenia in ovariectomized rats and promotes bone formation in osteoblasts. J Bone Miner Metab 29:149–158CrossRefPubMed

Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R (2008) Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 22:2465–2475CrossRefPubMed

Asaba Y, Ito M, Fumoto T, Watanabe K, Fukuhara R, Takeshita S, Nimura Y, Ishida J, Fukamizu A, Ikeda K (2009) Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 24:241–250CrossRefPubMed

10.

Donmez BO, Ozdemir S, Sarikanat M, Yaras N, Koc P, Demir N, Karayalcin B, Oguz N (2012) Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs. Pharmacol Rep 64:878–888CrossRefPubMed

11.

Kaneko K, Ito M, Fumoto T, Fukuhara R, Ishida J, Fukamizu A, Ikeda K (2011) Physiological function of the angiotensin AT1a receptor in bone remodeling. J Bone Miner Res 26:2959–2966CrossRefPubMed

12.

Pérez-Castrillón JL, Justo I, Silva J, Sanz A, Martín-Escudero JC, Igea R, Escudero P, Pueyo C, Diaz C, Hernández G, Dueñas A (2003) Relationship between bone mineral density and angiotensin converting enzyme polymorphism in hypertensive postmenopausal women. Am J Hypertens 16:233–235CrossRefPubMed

13.

Woods D, Onambele G, Woledge R, Skelton D, Bruce S, Humphries SE, Montgomery H (2001) Angiotensin-I converting enzyme genotype-dependent benefit from hormone replacement therapy in isometric muscle strength and bone mineral density. J Clin Endocrinol Metab 86:2200–2204PubMed

14.

Iusuf D, Henning RH, van Gilst WH, Roks AJ (2008) Angiotensin-(1–7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 585:303–312CrossRefPubMed

15.

Lynn H, Kwok T, Wong SY, Woo J, Leung PC (2006) Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 38:584–388CrossRefPubMed

16.

Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24:581–589CrossRefPubMed

17.

Sato A, Suzuki H, Nakazato Y, Shibata H, Inagami T, Saruta T (1994) Increased expression of vascular angiotensin II type 1A receptor gene in glucocorticoid-induced hypertension. J Hypertens 12:511–516CrossRefPubMed

18.

Barreto-Chaves ML, Aneas I, Krieger JE (2001) Glucocorticoid regulation of angiotensin-converting enzyme in primary culture of adult cardiac fibroblasts. Am J Physiol Requl Integr Comp Physiol 280:R25–R32

19.

Roy SG, De P, Mukherjee D, Chander V, Konar A, Bandyopadhyay D, Bandyopadhyay A (2009) Excess of glucocorticoid induces cardiac dysfunction via activating angiotensin II pathway. Cell Physiol Biochem 24:1–10CrossRefPubMed

20.

Garcia P, Schwenzer S, Slotta JE, Scheuer C, Tami AE, Holstein JH, Histing T, Burkhardt M, Pohlemann T, Menger MD (2010) Inhibition of angiotensin-converting enzyme stimulates fracture healing and periosteal callus formation—role of a local renin-angiotensin system. Br J Pharmacol 159:1672–1680CrossRefPubMedCentralPubMed

21.

Izu Y, Mizoguchi F, Kawamata A, Hayata T, Nakamoto T, Nakashima K, Inagami T, Ezura Y, Noda M (2009) Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem 284:4857–4864CrossRefPubMed

22.

Haznedaroglu IC, Ozturk MA (2003) Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int J Biochem Cell Biol 35:867–880CrossRefPubMed

23.

Mitani H, Bandoh T, Ishikawa J, Kimura M, Totsuka T, Hayashi S (1996) Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol 119:1269–1275CrossRefPubMedCentralPubMed

24.

Bergula AP, Huang W, Frangos JA (1999) Femoral vein ligation increases bone mass in the hindlimb suspended rat. Bone 24:171–177CrossRefPubMed

25.

McCarthy ID (2005) Fluid shifts due to microgravity and their effects on bone: a review of current knowledge. Ann Biomed Eng 33:95–103CrossRefPubMed

26.

Solomon DH, Mogun H, Garneau K, Fischer MA (2011) Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res 26:1561–1567CrossRefPubMed

27.

Yonqtao Z, Kunzheng W, Jingjing Z, Hu S, Jianqiang K, Quiyu L, Chunsheng W (2014) Glucocorticoids activate the local renin-angiotensin system in bone: possible mechanism for glucocorticoid-induced osteoporosis. Endocrine 47:598–608CrossRef

Title: Local renin-angiotensin system is associated with bone mineral density of glucocorticoid-induced osteoporosis patients
Authors: B. Shuai
Y. P. Yang
L. Shen
R. Zhu
X. J. Xu
C. Ma
L. Lv
J. Zhao
J. H. Rong
Publication date: 01-03-2015
Publisher: Springer London
Published in: Osteoporosis International / Issue 3/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-014-2992-y

At a glance: The STEP trials

Springer Medicine

Local renin-angiotensin system is associated with bone mineral density of glucocorticoid-induced osteoporosis patients

Abstract

Summary

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2015

Longitudinal assessment of oxytocin efficacy on bone and bone marrow fat masses in a rabbit osteoporosis model through 3.0-T magnetic resonance spectroscopy and micro-CT

Response to Hotta: High prevalence of vitamin D insufficiency and deficiency among patients with anorexia nervosa in Japan

Ethnic differences in urinary calcium and phosphate excretion between Gambian and British older adults

Family resemblance of bone turnover rate in mothers and daughters—the MODAM study

Adult bone strength of children from single-parent families: the Midlife in the United States Study

Ten-year incidences of self-reported non-vertebral fractures in Japanese patients with rheumatoid arthritis: discrepancy between disease activity control and the incidence of non-vertebral fracture